News

HRT cancer risk persists for three years

05-Mar-08

Women who have stopped taking oestrogen plus progesterone hormone replacement therapy (HRT) could still be at an increased risk of developing cancer three years later, US research suggests.
In 2002, the Women's Health Initiative (WHI) study was terminated early after oestrogen plus progesterone HRT was found to be linked to a 26 per cent increased risk of breast cancer and a 29 per cent higher risk of heart attack. 

Subsequently, women have been advised to take HRT for as short a time as possible. But follow-up data from the WHI suggests that the increased cancer risk remains even after stopping HRT. 

The latest data comes from follow-up of 15,730 postmenopausal women, aged 50-79, who had participated in the WHI study.

Half the women had been taking oestrogen plus progesterone HRT, but stopped the treatment in 2002 when the WHI study was abandoned. The rest of the women had taken placebo. 

Follow-up from July 2002 until March 2005, revealed that 281 women who had received HRT went on to develop cancer, compared with 218 who had not received HRT.

Overall, the combined risk of suffering heart disease, stroke, hip fracture or cancer increased by 12 per cent in the HRT group, compared with the placebo group. 

Researchers from the University of North Carolina hope the findings can help calculate optional use of HRT.

sanjay.tanday@haymarket.com

JAMA 2008; 299:1036-45

Comment below and tell us what you think 

Comments

Only registered users may comment. Log in now or register for a free account.

There are problems with your form submission.

Please review the errors shown below.



Forgot your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Quick search - use * for an abbreviated search, eg nico*

 
 

Latest Clinical Articles

Abnormal uterine bleeding

Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more

Chronic low back pain

Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Acute and sub-acute back pain

Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more

Show all clinical articles

MIMS Product News

New drug - Stelara

Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more

New high-strength nicotine patch

Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more

Prolonged-release aspirin

Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more

Jobs